Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

The role of long non-coding RNAs in glioblastoma progression and angiogenesis

EF 2011-12

Résumé
Glioblastoma is the most common adult brain tumour and one of the most difficult cancers to treat. Tumours, like normal human tissue, require a blood supply to deliver nutrients in order to survive. For this reason, there is an effort to develop drugs which prevent blood vessels from forming in a tumour as a means to treat cancer. Unfortunately, this approach has thus far had little effect on prolonging the survival of glioblastoma patients. To improve treatments for glioblastoma patients, it is essential to understand why these therapies fail. It was recently found that glioblastoma cancer cells can change into blood vessels within the tumour, which then contribute to supplying the necessary nutrients for tumour growth. However, blood vessels made from glioblastoma cells are not sensitive to drugs which prevent growth of normal blood vessels. This might help explain why current treatments which block vessel growth do not improve patient survival. Most current cancer treatments are inadequate and provide only temporary improvement, followed by relapse with the patient becoming sicker. Our aim is to understand how glioblastoma cancer cells can turn into blood vessels to feed the tumor and ultimately to develop new drugs to block this process. Although we will focus on glioblastoma, our findings will be relevant to all brains tumours, and cancer in general given that tumors require a blood supply to survive. The ultimate goal of this work is to develop more effective treatments for brain tumours and improve the lives of afflicted patients.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
252312
Name
Myskiw Chad
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The role of long non-coding RNAs in glioblastoma progression and angiogenesis
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer; Glioblastoma; Long Non-Coding Rnas; Mouse Models; Tumour Initiating Cells
Abstract
Glioblastoma is the most common adult brain tumour and one of the most difficult cancers to treat. Tumours, like normal human tissue, require a blood supply to deliver nutrients in order to survive. For this reason, there is an effort to develop drugs which prevent blood vessels from forming in a tumour as a means to treat cancer. Unfortunately, this approach has thus far had little effect on prolonging the survival of glioblastoma patients. To improve treatments for glioblastoma patients, it is essential to understand why these therapies fail. It was recently found that glioblastoma cancer cells can change into blood vessels within the tumour, which then contribute to supplying the necessary nutrients for tumour growth. However, blood vessels made from glioblastoma cells are not sensitive to drugs which prevent growth of normal blood vessels. This might help explain why current treatments which block vessel growth do not improve patient survival. Most current cancer treatments are inadequate and provide only temporary improvement, followed by relapse with the patient becoming sicker. Our aim is to understand how glioblastoma cancer cells can turn into blood vessels to feed the tumor and ultimately to develop new drugs to block this process. Although we will focus on glioblastoma, our findings will be relevant to all brains tumours, and cancer in general given that tumors require a blood supply to survive. The ultimate goal of this work is to develop more effective treatments for brain tumours and improve the lives of afflicted patients.
Competitiondate
201202
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Myskiw, Chad
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~